

# CONTENTS

---

KEY MESSAGES FROM THIS REPORT		1
	Summary of key data	2
	Key statistics by company cohort	5
INTRODUCTION		9
METHODOLOGY		11
SECTION 1: INTERNATIONAL PHARMACEUTICAL R&D EXPENDITURE AND SALES		17
	List of tables and figures	19
	Definitions	20
Section 2: PRODUCTS IN THE PIPELINE		47
	List of tables and figures	49
	Definitions	50
SECTION 3: NAS SUBMISSION, AUTHORISATION & MARKETING ACTIVITY		71
	List of tables and figures	73
	Definitions	74
DISCUSSION		91
REFERENCES		97
ACKNOWLEDGEMENT		98
APPENDIX 1 : Pharmaceutical companies invited to participate		101
APPENDIX 2 : <i>International Pharmaceutical R&amp;D Expenditure and Sales</i> questionnaire		103
APPENDIX 3 : <i>Products in the pipeline</i> questionnaire		105
APPENDIX 4 : <i>New active substance: submission, authorisation and marketing activity</i> questionnaire		107
APPENDIX 5 : OECD mean exchange rates		109
APPENDIX 6 : Therapeutic classification		111
APPENDIX 7 : New molecular entities first launched on to the world market in 1998		115
APPENDIX 8 : Data Tables		
	Section 1: International pharmaceutical R&D expenditure and sales	119
	Section 2: Products in the pipeline	127
	Section 3: New active substance: submission, authorisation and marketing activity	133